Progressive Supranuclear Palsy Epidemiology Forecast to 2030

April 16 18:32 2020
Progressive Supranuclear Palsy Epidemiology Forecast to 2030

Delveinsight Business Research
DelveInsight’s ‘Progressive Supranuclear Palsy Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Progressive Supranuclear Palsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Progressive Supranuclear Palsy (PSP) is an uncommon degenerative neurological disorder—the disease results from damage to nerve cells in the brain that causes the gradual deterioration of balance and walking; speech difficulties, trouble in swallowing, diminished vision, changes in mood and behavior, and cognitive impairment. 

The classic syndrome of PSP (Richardson’s syndrome or RS) is characterized by postural instability and falls early in the disease course and by gaze dysfunction affecting the vertical eye movements more than the horizontal ones. 

The broad spectrum of syndromes that has been linked to PSP pathology also includes PSP-parkinsonism, a variant that presents with features suggestive of Parkinson’s disease (PD), pure akinesia with gait freezing, corticobasal syndrome, non-fluent variant primary progressive aphasia, behavioural variant frontotemporal dementia and even PSP presenting with cerebellar ataxia. 

The DelveInsight Progressive Supranuclear Palsy epidemiology report gives a thorough understanding of the Progressive Supranuclear Palsy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

It also provides treatment algorithms and treatment guidelines for Progressive Supranuclear Palsy in the US, Europe, and Japan. The report covers the detailed information of the Progressive Supranuclear Palsy epidemiology scenario in seven major countries (US, EU5, and Japan).

 

Key Highlights Of The Report

  • According to DelveInsight’s analysis, the total prevalent cases of Progressive Supranuclear Palsy (PSP) in 7MM were found to be 98,498 in 2017 and are estimated to increase by 2030. 

  • The United States has a second-highest prevalent population of Progressive Supranuclear Palsy after Japan, as assessed.

  • Among the EU-5 countries, the United Kingdom has the highest prevalent population with 12,681 cases and Spain has the lowest prevalent population with 9,604 cases in 2017.

 Progressive Supranuclear Palsy Epidemiology

Request for Sample Pages: 

https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-epidemiology-forecast

 

Progressive Supranuclear Palsy Epidemiology

Delveinsight’s Progressive Supranuclear Palsy epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. 

The Progressive Supranuclear Palsy epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. 

The Progressive Supranuclear Palsy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. 

It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

 

Scope of the Report

  • The report provides insight into the historical and forecasted patient pool of Progressive Supranuclear Palsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Progressive Supranuclear Palsy.

  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

  • The Progressive Supranuclear Palsy report provides a detailed overview explaining Progressive Supranuclear Palsy causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.

  • The Progressive Supranuclear Palsy Epidemiology Report and Model provide an overview of the risk factors and global trends of Progressive Supranuclear Palsy in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).

  • The report provides the segmentation of the Progressive Supranuclear Palsy epidemiology. 

 

Key Questions Covered In The Progressive Supranuclear Palsy Report Include:

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Progressive Supranuclear Palsy?

  • What are the key findings pertaining to the Progressive Supranuclear Palsy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?

  • What would be the total number of patients of Progressive Supranuclear Palsy across the 7MM during the forecast period (2017-2030)?

  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?

  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?

  • What is the disease risk, burden and unmet needs of the Progressive Supranuclear Palsy?

  • What are the currently available treatments of Progressive Supranuclear Palsy?

 

Key Benefit of Progressive Supranuclear Palsy Epidemiology Report 

  • The Progressive Supranuclear Palsy Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Progressive Supranuclear Palsy market

  • Quantify patient populations in the global Progressive Supranuclear Palsy market to improve product design, pricing, and launch plans

  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Progressive Supranuclear Palsy therapeutics in each of the markets covered

  • Understand the magnitude of Progressive Supranuclear Palsy population by its epidemiology

  • The Progressive Supranuclear Palsy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Table of Contents

  1. Key Insights 

  2. Executive Summary of Progressive Supranuclear Palsy

  3. Progressive Supranuclear Palsy Disease Background and Overview

  • Progressive Supranuclear Palsy Sign and Symptoms

  • Progressive Supranuclear Palsy Pathophysiology

  • Progressive Supranuclear Palsy Risk Factors

  • Progressive Supranuclear Palsy Diagnosis

  1. Progressive Supranuclear Palsy Patient Journey

  2. Progressive Supranuclear Palsy Epidemiology and Patient Population

  3. Progressive Supranuclear Palsy Treatment Algorithm, Current Treatment, and Medical Practices

  4. KOL Views on Progressive Supranuclear Palsy 

  5. Progressive Supranuclear Palsy Unmet Needs

  6. Appendix

  7. DelveInsight Capabilities

  8. Disclaimer

*The table of contents is not exhaustive; will be provided in the final report

 

About  DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Related Reports:

Progressive Supranuclear Palsy Market Insight, Epidemiology and Market Forecast 2030

DelveInsight’s “Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Progressive Supranuclear Palsy , historical and forecasted epidemiology as well as the Progressive Supranuclear Palsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.  

Progressive Supranuclear Palsy Pipeline Insights, 2020

Progressive Supranuclear Palsy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Progressive Supranuclear Palsy market.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/